Print

Clarus Therapeutics Strengthens Patent Estate With Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product  
9/19/2012 9:26:21 AM

NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same." The U.S. patent relates to the formulation of testosterone prodrugs for oral administration with enhanced absorption and bioavailability. Specifically, the patent covers Clarus' oral testosterone product, CLR-610, which is in Phase 3 development for the clinical management of low testosterone in men. It is expected that the patent will provide Clarus with U.S. patent protection at least through April 2028. Additional patent applications are pending in the U.S. and other key countries.
//-->